Evotec stock trades close to its 52-week low as liquidity tops EUR 465.6 million
Published on 08/31/2026 at 08:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec SE stock (ISIN DE0005664809) is trading only a few percent above its recent 52-week low as of late August 2026, even though the company reports liquidity of EUR 465.6 million at the end of the first half of 2026. Per a recent market overview dated August 30, 2026, the shares closed at EUR 3.37, which is just 5.5 percent above the 52-week low of EUR 3.19 marked in July 2026. That same snapshot shows a year-to-date performance of minus 38 percent for Evotec’s stock, underlining the pressure on the valuation despite a strengthened balance sheet. For investors, the tension between a weak share price and solid liquidity now frames the discussion around the company’s next strategic steps.
Share price holds just above 52-week low
Recent trading data compiled in a German market commentary on August 30, 2026 indicates that Evotec shares closed at EUR 3.37 at the end of the latest trading session, only slightly above the 52-week low of EUR 3.19 reached in July 2026. The article notes that this closing level leaves the stock just 5.5 percent higher than that July low, highlighting how the shares remain pinned close to the bottom of their one-year range. The same piece reports that Evotec’s stock has declined by 38 percent since the beginning of 2026, placing the company firmly among the underperformers in Europe’s listed biotech sector for the year. This performance context shows that the current price weakness is not just a technical fluctuation but a sustained downtrend over several months. Investors who entered the stock at the start of the year have therefore seen a clear double-digit percentage loss by late August 2026.
Another short-term technical snapshot published on August 30, 2026 adds further color, stating that Evotec’s shares delivered a weekly performance of plus 0.9 percent in the most recent week. Over that timeframe, the stock traded between a weekly low of EUR 3.238 and a weekly high of EUR 3.52, suggesting that the current trading band is relatively narrow and centered slightly above the 52-week trough. The same overview lists a market capitalization of EUR 597.29 million as of August 30, 2026, which implies that the market is assigning a sub-billion-euro value to Evotec despite its international partnerships and pipeline. Taken together, the weak year-to-date performance, the proximity to the 52-week low, and the modest market cap paint a picture of a company that has lost investor confidence but still retains scale and assets that could support a recovery if sentiment improves.
Liquidity strengthened by asset sale
A detailed analysis of Evotec’s financial position published on August 30, 2026 focuses on the company’s liquidity and its use of portfolio measures to bolster the balance sheet in the first half of 2026. According to this report, Evotec held liquid funds of EUR 465.6 million at the end of the first half of 2026. That figure reflects cash and cash equivalents after transactions including the sale of the Tubulis stake, which contributed to an increase in available liquidity compared with earlier periods. While the article does not quantify the exact prior-year liquidity in euro terms, it emphasizes that the disposal and related financing measures have strengthened Evotec’s ability to fund its research programs and manage ongoing operating expenses. In the context of a market capitalization of EUR 597.29 million, the reported liquidity of EUR 465.6 million suggests that a significant proportion of Evotec’s value is currently represented by cash and near-cash assets at mid-2026, an unusual situation for a research-focused biotech group.
The same liquidity-focused commentary notes that the financing measures undertaken by Evotec in recent months have improved balance-sheet resilience but have not yet triggered a sustained turnaround in the share price. As of the reported closing level of EUR 3.37 on August 30, 2026, the stock trades only marginally above its 52-week low, illustrating that investors remain cautious despite the cash buffer. This disconnect between operational funding strength and market valuation could reflect concerns around the timing and visibility of future revenue growth, the risk profile of the development portfolio, or the broader sentiment toward European biotech issuers in 2026. Historically, such situations where cash accounts for a large share of market capitalization often prompt discussions among investors about whether the market is underpricing the company’s pipeline or appropriately discounting potential execution and regulatory risks.
The weekly technical data set framed around August 30, 2026 further reinforces the impression that Evotec’s stock is struggling to gain momentum. With the weekly performance limited to plus 0.9 percent and a trading range between EUR 3.238 and EUR 3.52, the shares are oscillating in a tight band slightly above the recent low rather than embarking on a strong rebound. The reported market capitalization of EUR 597.29 million at that same timestamp, when compared with the liquidity figure of EUR 465.6 million at the end of the first half of 2026, implies that the remaining valuation assigned to Evotec’s intangible assets, partnerships, and pipeline is modest. For long-term investors, the numerical relationship between liquidity and market capitalization may raise the question of whether the stock is pricing in heightened risk or offering a discounted entry into the company’s development programs.
Management changes and governance context
Corporate governance has also been active in recent weeks, adding a further dimension to the investment case. A news item dated August 31, 2026 reports that a new member, identified as Wheeler, is entering Evotec’s supervisory body, signaling ongoing refreshment of the company’s oversight structures. The same article situates this appointment in a phase where Evotec, headquartered in Hamburg, is working to rebuild trust among investors after a period of share-price weakness. The report underscores that the share price on the referenced date is EUR 3.37, reinforcing the picture of a stock trading well below levels seen only months earlier. The combination of board changes and a depressed valuation often reflects a broader strategic recalibration, as companies adjust governance frameworks to support new priorities, sharpen capital allocation, or respond to market feedback.
For shareholders, the reported supervisory board change may be interpreted as an effort by Evotec to strengthen oversight and expertise as it navigates a challenging environment. The fact that the share price has lost 38 percent since the start of 2026, as highlighted in the liquidity analysis dated August 30, 2026, means that any governance adjustments are occurring against a backdrop of meaningful capital erosion for existing investors. Numerically, a decline of 38 percent from the beginning of 2026 to late August 2026 implies that an investor who held EUR 10,000 worth of Evotec shares at the start of the year would now hold stock valued at EUR 6,200, assuming the same percentage change applies. The entry of a new supervisory board member could signal a push to address strategic or operational concerns that contributed to this performance, though the underlying article does not specify particular initiatives or restructuring measures tied directly to the appointment.
The interplay between governance changes and balance-sheet strength may thus become a central narrative for Evotec over the coming quarters. With liquid funds of EUR 465.6 million at June 30, 2026 and a market capitalization of EUR 597.29 million as of August 30, 2026, the company has the financial flexibility to pursue partnerships, invest in clinical development, or consider selective acquisitions. At the same time, the sharp year-to-date share-price decline and the proximity to the 52-week low suggest that investors will closely scrutinize management’s capital deployment decisions and pipeline progress. If governance adjustments enhance strategic clarity and operational execution, they could help close the gap between Evotec’s cash-rich balance sheet and its subdued market valuation.
Evotec’s discovery and development platform
Beyond the immediate market and governance discussion, Evotec’s business model remains centered on a discovery and development platform designed to support pharmaceutical and biotechnology partners across multiple disease areas. The company is known for integrating early-stage drug discovery, preclinical development, and selected clinical capabilities into a comprehensive offering that can accelerate the path from target identification to candidate selection. This platform typically combines high-throughput screening, medicinal chemistry, biology, and translational research, allowing partners to tap into Evotec’s infrastructure rather than building every capability in-house. As a result, Evotec generates revenues through service agreements, milestones, and potential downstream participation in successful programs, though the exact revenue figures for the most recent quarter are not detailed in the available sources dated around August 31, 2026.
The strategic logic behind such a platform is to diversify risk across multiple partnered projects while retaining exposure to breakthrough therapies. In practice, this means that Evotec’s pipeline is partly composed of partnered programs where external pharmaceutical companies may ultimately take compounds into late-stage development and commercialization. For investors, the platform’s value lies in the breadth and depth of these collaborations, the scientific quality of the discovery engine, and the company’s ability to convert research output into clinical candidates that advance through the regulatory process. When seen against the reported liquidity of EUR 465.6 million at the end of the first half of 2026, the platform model suggests that Evotec has both the infrastructure and funding to sustain long-term research, even though the current market capitalization of EUR 597.29 million reflects skepticism in the near term.
In addition, Evotec’s focus on areas such as neurology, oncology, and metabolic diseases has historically positioned it in segments where unmet medical need is high and the potential commercial upside for successful therapies can be significant. The mix of discovery services and proprietary projects means that the company’s revenue profile may depend on both steady service income and more volatile milestone payments. While concrete revenue or earnings figures for the most recent quarter are not specified in the articles dated August 30 and August 31, 2026, the strengthened liquidity reported at mid-2026 indicates that funding capacity is not the primary constraint on ongoing research. Instead, the main challenge appears to lie in convincing the market that the platform and pipeline can translate into a trajectory of earnings growth that justifies a valuation well above the current level implied by a share price of EUR 3.37 and a market cap of EUR 597.29 million.
Stock level and investor takeaway
Against this backdrop, Evotec shares remain under pressure in late August 2026. With a recorded closing level of EUR 3.37 on August 30, 2026, the stock is only 5.5 percent above its 52-week low of EUR 3.19 reached in July 2026, and down 38 percent since the beginning of 2026 according to the same market commentary. The weekly trading band between EUR 3.238 and EUR 3.52, combined with a modest weekly performance of plus 0.9 percent and a market capitalization of EUR 597.29 million, suggests that the market has not yet repriced Evotec’s strengthened liquidity of EUR 465.6 million at the end of the first half of 2026 into a sustained recovery. For investors, the numbers frame a clear trade-off: a balance sheet that compares favorably with the company’s market value versus a share price history that signals skepticism about the pace and visibility of future growth.
Read more
More on Evotec stock and its recent trading and liquidity context is available via a German-language market data overview dated August 30, 2026 at boerse-express.com, which details the share price of EUR 3.37, the 52-week low of EUR 3.19, the year-to-date decline of 38 percent, and the influence of recent financing measures on the company’s balance sheet. Another data-driven commentary at wallstreet-online.de from August 30, 2026 provides the weekly trading range between EUR 3.238 and EUR 3.52 and the market capitalization of EUR 597.29 million as of late August 2026, complementing the liquidity and governance insights with a technical chart perspective.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVO
Exchange: Xetra
Price (as of August 30, 2026, 4:00 p.m. local time): EUR 3.37
Market cap: EUR 597.29 million (as of August 30, 2026)
Sector / Industry: Biotechnology / Life-sciences services
Index membership: TecDAX
